MoT Cell Line Screening for Treg Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for developing therapies that target Regulatory T cells (Tregs) are hindered by the need for large volumes of peripheral blood and the heterogeneity of Treg populations, limiting the ability to specifically enhance or suppress Treg activity for autoimmune diseases and cancer treatment.
Innovation Solution
A human cell line, MoT (ATCC CRL-8066), with Treg-like activity is identified, expressing markers such as CD4, CD25, GITR, and PD-L1, which can be used as a screening tool to modulate Treg activity by incubating CD4+ cells with MoT cells in the presence of suspected agents, allowing for the detection of changes in Treg activity through cell proliferation and cytokine secretion measurements.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Tregs are isolated from human peripheral blood for therapy development, then Treg activity can be studied, but large volumes of peripheral blood are required and heterogeneity limits specificity
Solution Approach 1:
The patent creates a Treg-like cell line (MoT cells) that copies the essential functions and markers of natural Tregs without requiring isolation from peripheral blood. This cell line expresses Treg markers (CD4, CD25, FoxP3, GITR, CCR4) and performs suppressive functions, serving as a reproducible model system that eliminates the need for large blood volumes while maintaining therapeutic relevance.
Solution Approach 2:
The patent transforms Treg study from using primary isolated cells with variable characteristics to using an immortalized cell line with stable, defined parameters. The MoT cell line provides consistent expression of Treg markers and functions across multiple passages, enabling reliable high-throughput screening without the heterogeneity inherent in freshly isolated Tregs.
2Quantity of substance
If Tregs are expanded in vitro using IL-2, TGF-β and/or inhibition of PI3K and mTOR, then Treg population can be increased, but mixed populations result reducing specificity
Solution Approach 1:
Rather than attempting to expand and maintain heterogeneous primary Treg populations, the patent creates a homogeneous Treg-like cell line that inherently possesses the desired suppressive functions. The MoT cells were derived through immortalization and selection processes that stabilized a uniform population with consistent Treg marker expression and suppressive activity, eliminating the need for complex expansion protocols that generate mixed populations.
3Adaptability or versatility
If therapies are developed to enhance or suppress Treg activity, then treatment options for autoimmune disease and cancer can be expanded, but no FDA approved therapies currently exist due to methodological limitations
Solution Approach 1:
The MoT cell line serves as a standardized, manufacturable platform for therapy development. Unlike primary Tregs that require complex isolation and expansion from donor blood, the immortalized MoT cells can be propagated indefinitely in defined media, providing a scalable, GMP-compatible system for generating therapeutic products with consistent quality attributes.
Solution Approach 2:
The patent performs preliminary characterization of the MoT cell line to establish baseline Treg marker expression and suppressive function before using it for drug screening. This pre-validation ensures that the cell line is appropriately suited for its intended purpose as a screening tool, allowing researchers to confidently interpret screening results without needing to re-validate each experimental setup.
Data Source
AI summary
The present invention includes a method for screening one or more agents that modulate Regulatory T cell (Treg) activity, the method comprising the steps of: incubating a population CD4+ cells isolated from human blood peripheral mononuclear cells the CD4+ cells in contact with MoT cells in the presence of the one or more agents suspected of modulating Treg activity; detecting activation of the CD4+ cells without or with the agent; and comparing the activation of the CD4+ cells without or with the agent, wherein a change in activation following incubation with the agent relative to the activation of the PBMCs following incubation without the agent indicates that the agent is a modulator of Treg activity.